Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Intracerebral hemorrhage in COVID-19: A narrative review

Nikolaos Panagiotis Margosa, Andreas Stylianos Meintanopoulosa, Dimitrios Filiogloua, John Ellulb

a School of Medicine, University of Patras, Institutional Address: University Campus, 26504 Rio, Greece
b Department of Neurology, University Hospital of Patras, Institutional address, 26500 Rio, Patras, Greece

A R T I C L E   I N F O

Article history:
Received 29 November 2020
Accepted 3 May 2021

Keywords:
Intracerebral
Hemorrhage
Intraparenchymal
Intracranial
COVID-19
Hemorrhagic stroke

A B S T R A C T

Coronavirus Disease 19 (COVID-19) pandemic affects the worldwide healthcare system and our understanding of this disease grows rapidly. Although COVID-19 is a mainly respiratory disease, neurological manifestations are not uncommon. The aim of this review is to report on the etiology, clinical profile, location, and outcome of patients with intracerebral hemorrhage (ICH) and COVID-19. This review includes 36 studies examining ICH in the clinical presentation of COVID-19. Overall, 217 cases with intracranial hemorrhage, of which 188 ICHs, were reported. Generally, a low incidence of both primary and secondary ICH was found in 8 studies [106 (0.25%) out of 43,137 hospitalized patients with COVID-19]. Available data showed a median age of 58 years (range: 52–68) and male sex 64%, regarding 36 and 102 patients respectively. Furthermore, 75% of the patients were on prior anticoagulation treatment, 52% had a history of arterial hypertension, and 61% were admitted in intensive care unit. Location of ICH in deep structures/basal ganglia was ascertained in only 7 cases making arterial hypertension an improbable etiopathogenetic mechanism. Mortality was calculated at 52.7%. Disease related pathophysiologic mechanisms support the hypothesis that SARS-CoV2 can cause ICH, however typical ICH risk factors such as anticoagulation treatment, or admission to ICU should also be considered as probable causes. Physicians should strongly suspect the possibility of ICH in individuals with severe COVID-19 admitted to ICU and treated with anticoagulants. It is not clear whether ICH is related directly to COVID-19 or reflects expected comorbidity and/or complications observed in severely ill patients.

1. Introduction

1.1. Pathophysiology and transmission of COVID-19

Coronavirus disease (COVID-19) has become the most difficult challenge for modern medicine, as it has manifested into a worldwide pandemic by infecting over 61 million people as of November 24, 2020. The etiological factor is coronavirus 2 (SARS-CoV2), which infects the host cells by binding through the surface spike protein (mediated by transmembrane serine protease 2) to the human angiotensin converting receptor (ACE 2) [1–3].

SARS-CoV2 entry in cells causes cellular injury and finally cellular death. Subsequently, the formation of damage associated molecular patterns (DAMP’s) extracellularly and pathogen associated molecular patterns (PAMP’s) intracellularly leads to DAMP and PAMP recognition by pattern recognition receptors on endothelial cells and alveolar macrophages, thus triggering the induction of proinflammatory cytokine transcription factors [4]. This leads to a pulmonary recruitment of macrophages and dendritic cells which phagocytose SARS-CoV2 and migrate to secondary lymphoid organs further propagating cytokine release. Increased cytokine levels are associated with more severe disease [5].

Transmission of SARS-CoV2 occurs through both direct or indirect means. Human to human transmission via inhalation of mucosalivary droplets which can remain intact, contagious and airborne for at least 3 h is considered the direct mechanism of transmission [6]. Contact with contaminated objects and then with mucous membranes can indirectly transmit the disease. SARS-CoV2 can also be transmitted from asymptomatic carriers without any radiological finding or patients who are in the incubation period [7].

1.2. Clinical characteristics of COVID-19

COVID-19 disease is characterized by a variety of clinical manifestations ranging from asymptomatic state to Acute Respiratory Distress Syndrome (ARDS) and multiorgan failure, but primary involves the respiratory system. Initial symptoms typically include...
fever, dry cough, sore throat, headache, fatigue, myalgia and shortness of breath [8]. Confusion, diarrhea, nausea and vomiting, rhinorrhea and skin rash, as well as conjunctivitis have also been reported in COVID-19 [7]. Anosmia and dysgeusia are the most common early neurological symptoms of COVID-19 (occurring to up to 80% of patients) [9,10], whilst encephalopathy is common in critically ill patients [11]. Ischemic and hemorrhagic strokes have also been reported and must be taken into consideration when assessing COVID-19 patients with known vascular risk factors [12]. Other neurological manifestations include Guillain-Barré syndrome and its variants, meningocerebralitis, acute disseminated encephalomyelitis, acute hemorrhagic necrotizing encephalopathy [11], generalised myoclonus, ataxia [13], posterior reversible encephalopathy syndrome, and seizures [11].

Abnormal coagulation parameters have also been observed and are associated with poor prognosis [14]. Additionally, SARS-CoV2 can cause liver dysfunction, acute kidney failure, acute myocarditis, heart failure and shock [10]. In patients who demonstrate an extreme rise in cytokines by the end of the first week, the disease can progress to pneumonia, ARDS, multisystem failure, and finally death [4].

1.3. Intracerebral hemorrhage in patients with COVID-19

Intracerebral hemorrhage (ICH) is a very rare but well documented complication of COVID-19. Primary ICH could occur in the absence or presence of known risk factors, such as arterial hypertension (HTN) or anticoagulation therapy (pre-treatment of unrelated disease or COVID-19 thromboprophylaxis). ICH may also be secondary to hemorrhagic transformation of an acute ischemic stroke or to complications of revascularization procedures; cerebral sinus thrombosis can also cause brain hemorrhage. Symptoms are usually focal, depending on the affected cerebral region but can also be non-specific. Patients with ICH typically present with severe headache, hemiparesis, eye deviation and impaired levels of consciousness. Brain imaging such as a rapid computed tomography (CT) is mandatory and must be performed urgently in order to distinguish between ICH and ischemic stroke [15]. CT angiography is a highly specific test and is suitable for bleeding source detection. Other options include brain magnetic resonance imaging and angiography [16]. Treatment usually involves hemodynamic and neurological stabilization, management of the underlying conditions and, in selected cases, neurosurgical intervention [17].

2. Methodology

Pubmed and Google Scholar were used as search tools to identify relevant studies and articles, with the last search being performed on November 20th 2020. Keywords include: “COVID-19”, “Intracerebral”, “Cerebral” and “Hemorrhage”. Inclusion criteria parameters include: All article types written in English language and published in the last year that examine COVID-19 in combination with ICH. Articles excluded from the review were not written in English language and/or did not provide a full-text publication. Our initial search yielded 2365 search results out of which 36 original studies met our inclusion criteria.

The aim of this narrative review is to report on the etiology, clinical profile, location, and outcome of patients with ICH and COVID-19.

3. Results

Thirty-six original studies, case series and reports, reported a total of 217 cases with intracranial hemorrhage, of which 188 were ICHs (Table 1) [2,18–52]. However, in some reports intracranial hemorrhage was used as a broader term co-reporting ICH with other types of brain hemorrhage (subarachnoid hemorrhage (SAH), primary intraventricular, subdural hemorrhage).

3.1. Incidence

Data from 8 studies [18,25] including 43,137 hospitalized patients with COVID-19 reported a total number of 122 (0.28%) cases of intracranial hemorrhage, of which 106 (0.25%) were ICHs. Of the 106 reported ICH cases, 80 (75.5%) were considered primary, whilst the remaining 26 were all secondary to hemorrhagic transformation of ischemic stroke. The remaining 16 cases developed other type of intracranial hemorrhage (8 were SAH and 8 could not be identified).

3.2. Age and sex

Four studies [20,22,23,26] reported 63 hospitalized patients with intracranial hemorrhage with a mean age that ranged from 57 (±7.0) to 69.4 (±9.8) years; a median age that ranged from 49.5 (range: 39.5 – 62.8) to 62 (range: 37 – 83) was reported in 3 studies regarding 70 patients [18,21,27]. A median age of 58 years (range: 52–68) was calculated in 36 cases of ICH regarding 23 studies [2,24,29,31,33–44,46–52].

Male sex was reported in 134 (65%) out of 206 patients with intracranial hemorrhages, [18–23,26,27,29–52] and 65 (64%) out of 102 patients with ICH [2,18,22,26,29,31–52].

3.3. History of arterial hypertension and prior use of anticoagulants

History of arterial HTN was reported in 89 (54%) out of 164 patients with intracranial hemorrhage, [2,18,19,21–24,26,27,30–3,4,36,41,42,44–47,49,51] and in 45 (52%) out of 87 patients with ICH [2,18,22,24,26,31–34,36,41,42,44–47,49,51].

Anticoagulation prior to onset of brain hemorrhage was administered in 88 (75%) out of the 118 patients with intracranial hemorrhage [2,18,21–23,29–31,33–35,39,42–48,49,50], and 54 (75%) of the 72 patients with ICH [2,18,22,29–31,33–35,39,42–48,49,50]. The type of anticoagulation treatment was reported in 67 cases with intracranial hemorrhages; in 62 of them anticoagulation treatment was initiated in-hospital (39 received unfractionated heparin (UFH), 16 low molecular weight heparin (LMWH), 4 heparin & argatroban, 3 heparin switched to LMWH), and 5 have been on long term anticoagulant treatment (3 were receiving warfarin, and 2 warfarin/dabigatran) [2,18,21,29–31,33–35,39,42,44,49,50].

3.4. Intensive care unit admission prior to intracranial hemorrhage

ICU admission prior to brain hemorrhage was reported in 73 (64%) of the 115 patients who subsequently developed intracranial hemorrhage, [2,21–23,26,27,29–35,38–52] and 42 (61%) of the 69 who subsequently developed ICH [2,22,26,29–35,38–52].

3.5. Time from COVID-19 symptoms to diagnosis of hemorrhage

Median time from COVID-19 symptoms to diagnosis of brain hemorrhage ranged from 1 to 32 days amongst 6 reviewed studies [2,18–20,23,27].

3.6. Etiology and location of ICH

Out of 188 ICHs, 149 (79%) were primary, [2,18–28,30–38,41,43–48,50] including those with or without known risk factors such as arterial HTN, prior use of anticoagulants or extracorporeal membrane oxygenation (ECMO); 29 ICHs were secondary to hemor-
Table 1
Reviewed studies and findings (n = 36).a

| Study                  | Number of intracranial hemorrhages/total number of cases with COVID-19 (n of ICH) | Sex (male) n | Age in years | History of HTN n | ICH admission prior to hemorrhage | Anti-coagulation therapy at the time of ICH n | Hemorrhage location n | Etiology of hemorrhage | Days from COVID-19 to stroke diagnosis Median (range) | Other Findings |
|-----------------------|----------------------------------------------------------------------------------|-------------|--------------|------------------|----------------------------------|-----------------------------------------------|-----------------------|-----------------------|------------------------------------------------------|---------------|
| Dogra et al. [18]     | 33/3824 (33 ICH)                                                                 | 26          | Median (range): 62 (37 – 83) | 16               | NR                               | 22 {15 UFH, 3 on UFH + LMWH, 3 UFH + argatroban, 1 enoxaparin} 3 (type of drug NR) + 2 long term (warfarin and dabigatran) | NR                    | 7 Primary ICH, 26 Secondary to HT of ischemic stroke | 17 (8–23)                                           | Long-term treatment prior to ICH: 7 on aspirin, 2 aspirin + clopidogrel, 1 on cilostazol, 1 clopidogrel ICH score median: 2 (range: 1–2)Mortality: 42.4% (14/33) ICH score median: 3 (range: 1–3) NIHSS score median: 22 (7 – 25)Mortality:16/28 (58,3%) |
| Siegler et al. [19]   | 28/14,483 (20 ICH)                                                               | 18          | –            | 18               | NR                               | 13 supratentorial ICHs 7 infratentorial ICHs 8 other types of intracranial hemorrhage ICHs NR, 2 SAH | Primary ICHs          | 3.5 (1 – 7)                                      |                                                     |                                                           |
| Shahjouei et al [20]  | 27 / 17,799 (25 ICH)                                                              | 19          | Mean (SD) 62.5 (15.3)          | NR               | NR                               | 17 (13 heparin, 2 enoxaparin, 2 long-term warfarin)                         | Primary ICHs          | 1 (0–5)                                           | NIHSS score median: 13 (8 – 17) ICH score median: 3 (2 – 4)                                                     |
| Kvernland et al. [21] | 19/4071 (16 ICH)                                                                  | 15          | Median (range): 60 (51 – 63)   | 8                | 16                               | 6 lobar intraparenchymal (IPH) ICHs 4 multifocal cortical, 1 multifocal IPH, 1 subcortical, 2 cortical, 2 cerebellar 3 SAH | Primary ICHs          | NR                                                 | Mortality: 11/19 (57.9%) at follow-up 15 with HT of ischemic stroke were excluded from this study In 1 patient heparin was changed to argatroban. |
| Hernández-            | Fernández et al. [22]                                                            | 5 ICH/1683  | 4            | Mean (SD): 62.6 (7.2)          | 4                  | 3 (type NR)                      | 3 lobar ICHs (1 left frontal,1 left frontal with SAH expansion, 1 left temporal) 1 basal ganglia ICH 1 focal cortico-subcortical ICH with SAH involvement | Primary ICHs          | NR                                                 |                                                     |                                                           |
| Mortality: 2/5        | Rothstein et al. [23]                                                             | 8/844 (5 ICH) | 4            | Mean (SD) 57 (7.0)             | 6                  | 6 (type NR)                      | 5 lobar ICHs 3 SAH | Primary ICHs          | 25 (17–29)                                           | 4/7 treated with anticoagulants on simultaneous antiplatelet drugs 6/8 patients died in-hospital Died 13 days after ICH Cause of death: respiratory failure |
| Li et al. [24]        | 1 ICH/219                                                                        | NR          | 60           | NR               | 1                  | NR                               | NR                    | Primary ICHs          | 10                                                   |                                                           |
| Ling Mao et al. [25]  | 1 ICH/214                                                                        | NR          | NR           | NR               | NR                               | NR                    | Primary ICHs          | NR                                                 |                                                           |
| Behzandia et al. [26] | 23 ICH                                                                           | 11          | Mean (SD) 69.4 (9.8)           | 8                | 8                  | NR                               | 16 lobar ICHs 7 non-lobar ICHs | Primary ICHs          | NR                                                 |                                                     |                                                           |
| Nawabi et al. [27]    | 18 (5 ICH)                                                                        | 9           | Median (range): 49.5 (39.5 – 80) | 10               | 8                  | 8 (type NR)                      | 6 ICHs (4 lobar, 1 deep, 1 intratentorial) 2 primary intraventricular | Primary ICHs          | 1.5 (0 – 3)                                       | 1 case, ICH was diagnosed as a first manifestation of COVID-19. 1 patient on antiplatelets | (continued on next page)
| Study | Number of intracranial hemmorhages/total number of cases with COVID-19 (n of ICH) | Sex (male) n | Age in years | History of HTN n | ICU admission prior to hemorrhage | Anticoagulation therapy at the time of ICH n | Hemorrhage location n | Etiology of hemorrhage | Days from COVID-19 to stroke diagnosis Median (range) | Other Findings |
|---|---|---|---|---|---|---|---|---|---|---|
| Varathatraj et al. [28] | 9 ICH | NR | NR | NR | NR | NR | 9 SAH | 1 subdural hematoma | NR | Primary ICHs | NR | |
| Argiro et al. [29] | 6 ICH | 3 | Median (range) 64,5 (58.75 – 75) | NR | 4 | 5 - LMWH | 6 lobar ICHs (4 parietal, 1 temporal, 1 parieto-occipital and temporal) | Secondary to Cerebral Vein Thrombosis | NR | |
| Benger et al.[2] | 5 ICH | 3 | Median (range) 52 (45,5 – 59) | 4 | 4 | 5 (2 LMWH, 2 IV heparin, 1 warfarin) | 3 lobar ICHs, 1 multi-lobar ICH | Primary ICHs | 32 (14–38) | Patients with HTN developed lobar and multilobar ICHs whereas the patient with no history of HTN developed basal ganglia hemorrhage |
| Usman et al. [30] | 4 (3 ICH) | 3 | Mean (range) 53,7 (50,5–58,25) | 2 | 4 | 4 (3 UFH, 1 UFH + argatroban) | 3 lobar ICHs (1 frontal with SAH expansion, 1 frontal-temporal, 1 temporal with intraventricular expansion) | Primary ICH | 5,5 (3 – 18) from ECMO administration | All 4 on ECMO, All 3 patients with ICHs died. |
| Goncalves et al. [31] | 3 ICH | 1 | 56, 40s, 60s | 0 | 3 | 3 (2 enoxaparin, 1 UFH) | 2 Primary | 1 due to cerebral vein thrombosis | 15 (15, 16, 15) | Mortality: 3/3 |
| Bihlmaier et al. [32] | 3 ICH | 2 | Medium age (56.6) | 2 | 3 | NR | 3 multifocal | Primary ICH | NR | 3 patients on ECMO and 1 on long-term acetylsalicylic acid. Mortality: 3/3 |
| Fayed et al. [33] | 2 ICH | 1 | 57, 71 | 2 | 2 | 1 - heparin, 1 NR | 2 lobar ICHs (1 frontal, 1 occipital) | Primary ICHs | 20 | 1/2 patients died, following complications of ICH (cerebral circulatory arrest) One patient only on dual antiplatelet therapy Both died on the same day of ICH diagnosis |
| Morassi et al. [34] | 2 ICH | 2 | 57 (both cases) | 1 | 2 | 1 - enoxaparin | 2 lobar ICHs (1 Bilateral, 1 Frontal extending to ventricles) | Primary ICHs | 14 & 17 | |
| Ghan et al. [35] | 2 ICH | 1 | 59 (both cases) | NR | 2 | 2 (1 IV UFH and 1 apixaban switched to enoxaparin) | Locations NR (1 with SAH expansion, and 1 intraventricular expansion) | Primary ICHs | NR | |
| Agarwal et al. [36] | 2 ICH | 2 | 56, 72 | 1 | NR | NR | 1 pontine with intraventricular expansion | Primary ICH | 0 & NR | Mortality: 1/2 |
| Sharifi-Razavi et al. | 1 ICH | Male | 79 | NR | NR | NR | 1 right hemisphere, accompanied by intraventricular and | Primary ICH | 3 | Patient admitted for ICH and later confirmed COVID-19 infection, though mild symptoms of infection were |
| Study | Number of intracranial hemorrhages/total number of cases with COVID-19 (n of ICH) | Sex (male) | Age in years | History of HTN | ICU admission prior to hemorrhage | Anticoagulation therapy at the time of ICH | Hemorrhage location | Etiology of hemorrhage | Days from COVID-19 to stroke diagnosis Median (range) | Other Findings |
|-------|---------------------------------------------------------------------------------|------------|--------------|---------------|----------------------------------|--------------------------------------------|-------------------|-----------------------|------------------------------------------------|------------------|
| [37]  |                                                                                 |            |              |               |                                  |                                            |                   |                                      |                                               |                  |
| Bao et al. [38] | 1 ICH | Male | 38 | NR | 1 | NR | subarachnoid hemorrhage | Lobar ICH extending to basal ganglia. | Primary ICH | 0 | already present |
| Motoie et al. [39] | 1 ICH | Male | 50 | NR | 1 | 1 - IV UFH | Multifocal | Secondary ICH to HT of an ischemic stroke | 10 | Patient on ECMO. |
| Al-Obama et al. [40] | 1 ICH | Male | 36 | NR | 0 | NR | 1 lobar ICH (frontal with subdural extension) | Secondary ICH to COVID-19 encephalitis | Primary ICH | 6 | Patient died 8 days after ICH onset. |
| Kim et al. [41] | 1 ICH | Female | 53 | 0 | 0 | NR | 1 basal ganglia ICH (external capsule and putamen with intraventricular expansion) multi-loculated centered in the lentiform nucleus | Possibly secondary due to HT of ischemic stroke | Primary ICH | 5 | Radiologically ICH was attributed to viral encephalitis |
| Khattar et al. [42] | 1 ICH | Male | 42 | 1 | 1 | 1 - IV heparin | Possibly secondary due to HT of ischemic stroke | Primary ICH | 29 | Patient was positive for COVID-19 but was asymptomatic until the development of ICH. |
| Thu et al. [43] | 1 ICH | Male | 72 | NR | 1 | 0 | Lobar ICH (olfactory gyrus) | Multifocal | Primary ICH | 17 days post admission. | Clinical course was complicated by herniation due to ICH and patient deceased on the same day of ICH diagnosis. | Patient died 13 days after COVID-19 was diagnosed. |
| Gogia et al. [44] | 1 ICH | Male | 75 | 1 | 1 | 1 - Enoxaparin/ also on aspirin and clopidogrel | Multifocal | Primary ICH | NR | Prior MRI showed microbleeds. |
| Daci et al. [45] | 1 ICH | Female | 60s | 0 | 0 | 0 | Bilateral basal ganglia ICH with effacement of lateral ventricles | Primary ICH | 2 | – |
| Haddadi et al. [46] | 1 ICH | Female | 54 | 1 | 0 | 0 | Bilateral basal ganglia ICH | Primary ICH | 5 | – |
| Flores et al. [47] | 1 ICH | Male | 40 | 1 | 0 | 0 | Midbrain and Pons with intraventricular extension | Primary ICH | NR | – |
| Fraiman et al. [48] | 1 ICH | Female | 38 | NR | 0 | NR | Frontal lobe | Primary ICH | 0 | – |
| Rajdev et al. [49] | 1 ICH | Male | 62 | 1 | 1 | 1 - Heparin | NR | Possibly secondary due to HT of ischemic stroke | 12 | Patient expired after 27 days of hospitalization |
| Hussain et al. [50] | 1 ICH | Female | 69 | NR | 1 | 1 - LMWH | NR | Primary ICH | 24 | Patient also had aortic valve endocarditis. |
| Krett et al. | 1 ICH | Male | 69 | 1 | 1 | NR | Multifocal | Secondary to | 17 | Patient expired 18 days after admission |

(continued on next page)
rhagic transformation of ischemic stroke, [18,39,42,49] 7 to cerebral vein thrombosis, [29,31] and 3 to encephalitis/encephalopathy [40,51,52].

Location of ICH was reported in 114 cases; 64 (56%) were located at lobar regions, 7 at deep/basal-ganglia, 13 supratentorial (not specified in detail), 13 infratentorial (1 midbrain & pons, 1 pons, 3 cerebellar, 8 not specified in detail), 7 non-lobar (not specified in detail) and 10 were reported as multifocal [2,19–23,26,27,29–48,51,52].

3.7. Mortality

Available data from 5 studies with known in-hospital mortality in patients with intracranial hemorrhage, showed that 49 (52.7%) out of 93 patients deceased [18,19,21–23].

4. Discussion

ICH is an infrequent but life-threatening complication of COVID-19. In our current literature review, incidence ranged from 0.14% to 0.86% in hospitalised patients with COVID-19. This rate is clearly higher than the worldwide incidence of ICH which is 24.6/100,000 person-years or 0.0246% per person-year [53] Even though COVID-19 equally affects both genders, European studies have shown a 3-fold to 4-fold higher incidence of ICU admission in male patients [54]. The fact that 61% of ICH cases were developed in ICU care, may explain the predominance of males.

4.1. Potential mechanisms of SARS-CoV-2 mediated cerebrovascular injury

A proposed mechanism of ICH is through a virus related direct and indirect endothelial injury. The virus can directly invade host’s cells (in this case endothelial cells) via ACE2 receptor connection, causing cellular death. The indirect mechanism involves systemic factors such as inflammatory cytokine production, prothrombotic factors, activation of coagulation cascades, and complement-mediated microvascular thrombosis [2]. This thrombotic state has the potential of inducing ICH [55]. Finally, dysfunction of the blood–brain-barrier via tight junction complex disruption will occur leading to intracerebral hemorrhage [56].

4.2. Risk factors for intracerebral hemorrhage regardless of COVID-19 infection

The majority of patients with COVID-19 who developed ICH, had one or more risk factors such as arterial HTN, anticoagulation therapy or admission to the ICU due to severe disease. Acute spontaneous ICH is a common cause of critical illness and death among patients admitted to the ICU (regardless of COVID-19), making admission to the ICU a clearly important risk marker for the development of ICH [57]. Furthermore, SARS-CoV-2 can cause thrombotic events by both enhancing coagulation and weakening anticoagulation/fibrinolysis pathways [58]. Prothrombotic mechanisms have also been implied in the etiopathogenesis of ischemic strokes and are also observed in such patients; [58] with incidence ranging from 0.2% [59] to 1.4% [12]. Use of anticoagulants in acute ischemic stroke increases the risk of hemorrhagic transformation, which in our review was observed in 29 out of 188 ICHs.

The hypercoagulable state of SARS-CoV-2 combined with the high risk of thrombotic complications in critically ill patients admitted to ICU [60] makes pharmacological thromboprophylaxis or anticoagulation imperative in such cases; [61] mainly with the use of unfractionated heparin, LMWH, or fondaparinux; [62] furthermore, anticoagulation therapy appears to be independently
associated with ICH [63]. Lastly, ECMO, which can be applied in severe refractory COVID-19 pneumonia, may be a contributing factor to the development of ICH [63,64].

Arterial HTN can cause deep perforator arteriopathy/hypertensive arteriolosclerosis, and is the most common cause of primary ICH located in deep brain structures [65,66]. In our review, arterial HTN does not appear to be the main cause of ICH as only 7 out of 114 hemorrhages were located in deep brain structures indicating etiopathogenetic mechanisms other than arterial HTN, at least for the majority of cases.

Other risk factors for ICH should be accounted for, but were not reported by the studies that we reviewed. For instance, brain hemorrhage in COVID-19 has been associated with an unusual pattern of cerebral microbleeds in critically ill patients [67–70]. Small vessel disease (most commonly cerebral amyloid angiopathy), aneurysms, arteriovenous malformations, brain tumors, alcohol abuse and genetic contribution could also be considered as contributing factors [71].

4.3. Clinical presentation of intracerebral hemorrhage

Time between onset of COVID-19 symptoms and development of ICH diagnosis varied; a median of 1 or 1.5 days was observed in some studies [20,27] and up to 32 in other [2]. This variability could be partly explained by the deep sedation of patients admitted in ICU, which masks the typical symptoms of ICH. Physicians should strongly suspect the possibility of ICH in individuals with severe COVID-19 admitted to ICU and treated with anticoagulants.

4.4. Outcome

Typically, non-traumatic ICH is life-threatening emergency. Mortality reaches 40% at the first month and can rise up to 54% at 12 months [71,72]. Mortality in patients with ICH and COVID19 has not been reported in detail; data from our review show an in-hospital mortality of 52.7%; unfortunately no data are available for longer term follow-up. Of note, COVID-19 mortality in patients admitted in ICU is high (up to 49%) regardless of ICH development [73]. Finally, it is unclear whether ICH is related directly to COVID-19 or reflects expected comorbidity and/or complications observed in severely ill patients.

4.5. Limitations

Intracranial hemorrhage was used as a broader term in some reports and these patients could not be classified more specifically. Thus, SAH and other types of brain hemorrhage (i.e. primary intraventricular, subdural) are considered a confounding factor in our review. Publication bias was also an issue.

5. Conclusion

ICH is a rare clinical manifestation with high mortality rate in patients with COVID-19. Beyond typical risk factors for ICH, pathophysiologic involvement of SARS-CoV-2 can also be implicated. Although almost half of the reported cases had a history of arterial HTN, ICHs were mainly lobar, indicating other mechanism than hypertensive arteriolosclerosis. Admission to the ICU due to critical illness and the concomitant medical thromboprophylaxis or anticoagulation treatment seem clearly related with ICH. Still, it is unclear whether ICH is related directly to COVID-19 or reflects expected comorbidity and/or complications observed in severely ill patients. More original studies are needed in order to establish a clear relationship between ICH and COVID-19.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Bohn MK, Hall A, Sepiashvili L, Jung B, Steele S, Adeli K. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda) 2020;35(5):288–301.
[2] Benger M, Williams O, Siddiqui J, Srithra I. Intracerebral haemorrhage and COVID-19: Clinical characteristics from a case series. Brain Behav Immun 2020;88:940–4.
[3] Wang X, Ding YQ. From SARS to COVID-19: pathogens, receptor, pathogenesis and principles of the treatment. Zhonghua Bing Li Xue Za Zhi 2020;49(6):647–52.
[4] Yardapanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: Friend or foe?. Life Sci 2020;256:117900.
[5] Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 2020;54:62–75.
[6] Borak J. Airborne Transmission of COVID-19. Occup Med (Lond) 2020;70(5):297–9.
[7] Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chem Acta 2020;508:255–64.
[8] Osasuo H, Kharkoucha I, Bouhirim M, Daoudi N, Imtara H, The BN, et al. (COVID-19): evaluation and prevention. J Immunol Res 2019;2020(2020):1357983.
[9] Lozada-Nur F, Chainani-Wu N, Fortuna G, Sroussi H. Dysgeusia in COVID-19: possible mechanisms and implications. Oral Surg Oral Med Oral Pathol Oral Radiol 2020;130(3):344–6.
[10] Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020;56(2):106024.
[11] Almquist J, Granberg T, Torztszakais A, et al. Neurological manifestations of coronavirus infections – A systematic review. Ann Clin Transl Neurol 2020;7(10):2057–71.
[12] Nannoni S, de Groot R, Bell S, Markus HS. Stroke in COVID-19: a systematic review and meta-analysis. Int J Stroke 2020. 1747493020972922.
[13] Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci 2020;77:8–12.
[14] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18(4):844–7.
[15] Rordorf G, McDonald C. Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis. Uptodate. 2020. Available at: https://www.uptodate.com/contents/spontaneous-intracerebral-hemorrhage-pathogenesis-clinical-features-and-diagnosis.
[16] Asch CJ, Veithhaus BK, Rinkel GJ, Algra A, de Kort GA, Witkamp TD, et al. Diagnostic yield and accuracy of CT angiography, MR angiography, and digital subtraction angiography for detection of macrovascular causes of intracerebral haemorrhage: prospective, multicentre cohort study. BMJ 2015;351:h3762.
[17] Hampshir Jrd JC, Greengberg SM, Anderson CS, Becker K, Bendok BR, Cusimano M, et al. American heart association stroke council; council on cardiovascular and stroke nursing; clinical council on cardiovascular, guidelines for the management of spontaneous intracerebral hemorrhage: a Guideline for Healthcare Professionals From the Association. Stroke 2015;46(7):2032–60.
[18] Dogra S, Jain R, Cao M, Bilalogue S, Sagzag, D, Hochman, et al. Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis 2020;29(8):104984.
[19] Siegel JE, Cardona P, Arenillas JF, Talavera B, Guillen AN, Chavarría-Miranda A, et al. Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry [published online ahead of print, 2020 Sep 30]. Int J Stroke. 2020;1747493020959216.
[20] Shajhojri S, Naderi S, Li J, Khan A, Chaudhary D, Farahmand G, et al. Risk of stroke in hospitalized SARS-CoV-2 infected patients: a multidisciplinary study. EBioMedicine 2020;59:102939.
[21] Kvernland A, Kumar A, Yaghi S, Raz E, Frontier J, Lewis A, et al. Anticoagulation use and Hemorrhagic Stroke in SARS-CoV-2 Patients Treated at a New York Healthcare System [published online ahead of print, 2020 Aug 24]. Neurorict Care. 2020;1-12.
[22] Hernández-Fernández F, Sandoval Valencia H, Barrella-APonte RA, Collado-Jiménez R, Ayo-Martín O, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020;143(10):3089–103.
[23] Rochstein A, Oldridge O, Schwenness H, Do D, Cucciarra BL. Acute cerebrovascular events in hospitalized COVID-19 patients. Stroke 2020;51(9):e219–22.
[24] Li Y, Li M, Wang M, Hu Y, Chen S, He Q, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol 2020;2(5):279–84.
[25] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurool 2020;77(6):683–90. https://doi.org/10.1001/jamaneuro.2020.1127.
Behzadnia H, Omrani SN, Nozari-Golsefid H, Moslemi S, Aljani B, Reyhaniyan Z, et al. Ischemic stroke and intracerebral hemorrhage in patients with COVID-19. Rom J Neurol Neurosurg Psychiatr Rev. 2020;19(1):166–70.

Nawab M, Mostorodi A, Wildgruber M, Boulous G, Kraehling H, Schlunk F, et al. Clinical and Imaging Characteristics in Patients with SARS-CoV-2 Infection and Acute Intracerebral Hemorrhage. J Clin Med. 2020;9(8):2543. Published Online 2020 Aug 6.

Varaharaj A, Thomas N, Ellul MA, Davies N, Pollock TA, Tenorio EL, et al. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study [published correction appears in Lancet Psychiatry. 2020 Jul 14;7(1):125–6]. Lancet Psychiatry. 2020;7(10):875–882.

Argiriō R, Cirelli C, Sgreccia A, Del Sette B, Da Ros V. Cerebral hemorrhage related to vein thrombosis in Covid-19 patients in different Italian hospitals: View point for clinical and imaging implications [published online ahead of print, 2020 Jul 10]. J Neurol Sci. 2020:416;117023.

Usman AA, Han J, Acker A, Olia SE, Bermudez Cucchiara B, et al. A case series of 56 patients with COVID-19 complicated by intracerebral hemorrhage. Cureus. 2020;12(4):e7869.

Dixon L, Varley L, Coutsarova A, et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol Neuroimmunol Neuroinflamm. 2020;7(5):e789.

van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9(2):167–76.

Gebhard C, Regitz-Zagrosek V, Neuhäuser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11(1):29.

Román GC, Spencer PS, Reis J, Buguet A, Faris M, Katrak SM, et al. The neurology of COVID-19 revisited: a proposal from the environmental neurology specialty group of the world federation of neurology to implement international neurological registries. J Neurol Sci 2020;414:116884.

P.T. Ronaldson, TP. Davis Mechanisms of endothelial injury and blood–brain barrier dysfunction in stroke. InPrimer on Cerebrovascular Diseases, Academic Press. 2017:220–226.

Zhou YT, Tong DM, Wang SD, Ye S, Xu BW, Yang CX. Acute spontaneous intracerebral hemorrhage and traumatic brain injury are the most common causes of critical illness in the ICU and have high early mortality. BMC Neurol. 2018;18(1):127; Published 2018 Aug 27.

Haines MA. Pathogenesis and Treatment Strategies of COVID-19-Related Hypereutrapolytrophic and Thrombotic Clotting. Clin Appl Thromb Hemost. 2020;26:1076029620944497.

Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-analysis. Ann Neurol. Accepted Author Manuscript 2020.

Klof KA. Frup MJHA, van der Meir NJM, Arbous MS, Gommers D, Kant KM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148–56.

Ma A, Kase CS, Shoamaneh A, Abdalkader M, Pikula A, Sathya A, et al. Stroke and Thromboprophylaxis in the Era of COVID-19 [published online ahead of print, 2020 Oct 31]. J Thromb Thrombolysis. 2020;50(2):259–60.

Morotti Andrea, Goldstein Joshua N. Anticoagulant-associated intracerebral hemorrhage: causative or coincidental?. New Microbes New Infect. 2020;41:100908.

Ikram MA, Wieberdink RG, Koudstaal PJ. International epidemiology of intracerebral hemorrhage. Curr Atheroscler Rep 2012;14(4):300–6.

Fisher CM. Pathological observations in hypertensive cerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1951;14(5):374–40.

Katsanos AH, Palaiodimou L, Zand R, et al. The Impact of SARS-CoV-2 on Stroke Epidemiology and Care: A Meta-analysis. Ann Neurol. Accepted Author Manuscript 2020.

Lahiri S, Alessio M, Davis S, et al. Stroke and Thromboprophylaxis in the Era of COVID-19 [published online ahead of print, 2020 Sep 24]. J Thromb Thrombolysis. 2020;1:8.

Morotti Andrea, Goldstein Joshua N. Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages 2020;1(1):89–94.

Ickram MA, Wieberdink RG, Koudstaal PJ. International epidemiology of intracerebral hemorrhage. Curr Atheroscler Rep 2012;14(4):300–6.

Fisher CM. Pathological observations in hypertensive cerebral hemorrhage. J Neurol Neurosurg Psychiatry. 1951;14(5):374–40.

Fitzsimon L, Pugin D, Thieffry C, Lalive P, Vargas M. COVID-19 is Associated with an Unusual Pattern of Brain Microbleeds in Critically Ill Patients. J Neuroimaging. 2020;30(5):593–597. [J Gupta NA, Lien C, Iv M. Critical illness-associated cerebral microbleeds in severe COVID-19 infection. Clin Imaging. 2020;68:239-241.

Vattoth S, Abdelhady M, Alsoub H, Own A, Elsotouhy A. Critical illness-associated cerebral microbleeds in COVID-19 acute respiratory distress syndrome. Neurology 2020;95(11):498–509.

Wang S, Lu Y, Zheng X, Qiu J, Chen HS. The impact of cerebral hemorrhage on intracerebral hemorrhage and poor functional outcome of acute ischemic stroke patients treated with intravenous thrombolytic: a systematic review and meta-analysis. J Neurol 2017;264(7):1309–19.

An Sj, Kim TJ, Yoon BW, Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke 2017;19(1):3-10.

Fridman S, Bullrich MB, Jimenez-Ruiz A, Costantini P, Shah P, Just C, et al. Stroke Risk, phenotypes, and death in COVID-19: Systematic review and newly reported cases. Neurology 2020.

Grasselli G, Greco M, Zanella A, Albano Giovanni, Antonelli Massimo, Bellani Giacomo, et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA. Int Med 2020;180(10):1345-55.